General Catalyst invests in Heidi Health Trading Pty Ltd.
Funding Provisional 90% confidence first seen
Heidi Health Trading Pty Ltd. announced it raised $340 million in new funding to expand its AI Care Partner for clinical adoption. The round included a $100 million Series C led by Blackbird and an additional $240 million in growth investment from General Catalyst, with proceeds intended to deepen deployment across health systems. This matters because General Catalyst’s investment signals continued capital support for AI-driven clinical documentation and research-assistance tools in healthcare providers worldwide.
The deal
Heidi Health Trading Pty Ltd $340M Series C · announced 22 Sep 2026
Investors General Catalyst Blackbird
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Heidi Health Trading Pty Ltd. announced $340 million in new financing: a $100 million Series C led by Blackbird and a $240 million growth investment from General Catalyst. The company said the capital will be used to expand and deepen deployment of its AI Care Partner across health systems globally.
- Why it matters
- For healthcare leaders and technology decision-makers, this funding indicates that investors are still backing AI tools focused on clinical documentation and clinician research support at deployment scale, not just early pilots. The stated use of proceeds to deepen health-system adoption suggests more aggressive commercialization and implementation activity from Heidi, which may affect vendor evaluation, partnership, and competitive positioning decisions in provider organizations and digital health markets.
- Evidence
- The event is supported by Heidi Health Trading’s announced funding details as reported by SiliconANGLE AI, including the $100 million Series C led by Blackbird and the $240 million growth investment from General Catalyst. The single cited report is consistent within itself on the amount raised and intended use of funds, but it relies on the company’s announcement rather than multiple independent confirmations.
- What remains uncertain
- The coverage does not provide terms, valuation, revenue, customer adoption metrics, or timelines for deployment, so the business impact and execution risk cannot be verified from the report alone. It is also unclear how much of the growth investment is immediately deployable operating capital versus structured financing, and which specific health systems or geographies will be prioritized.
- Monitor next
- Watch for disclosed health-system deployment wins, expansion metrics, or implementation partnerships that show how quickly Heidi converts this financing into scaled clinical adoption.
Analytical support, not advice — assumptions and open questions stated above.